comparemela.com

Latest Breaking News On - Cris calsada - Page 1 : comparemela.com

BIO-TECHNE HIGHLIGHTS RECENTLY ANNOUNCED TOP-LINE BIOMARKER DATA FROM PARTNER, REGULUS THERAPEUTICS, USING THE COMPANY S PROPRIETARY TECHNOLOGY

MINNEAPOLIS, May 22, 2024 /PRNewswire/ Bio-Techne Corporation and Regulus Therapeutics Inc., a biopharmaceutical company focused on the discovery and development of innovative medicines.

San diegoUnited statesBio techne exosomedxCris calsadaDavid clairSarah suttonBio techne corporationPrnewswire bio techne corporationRegulus therapeutics incProtein sciences segmentInvestor relations corporate developmentTechne corporationAutosomal dominant polycystic kidney diseaseSimple westernWill geistProtein sciences

Regulus Therapeutics Reports First Quarter 2023 Financial Results and Recent Updates

/PRNewswire/ Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines.

United statesSan diegoCris calsadaSarah suttonJay haganRegulus therapeutics incProgram updatesRnas the company or regulusEnterprise associatesDevelopment rd expensesExchange commissionAutosomal dominant polycystic kidney diseaseMultiple ascending dosePrivate placementFederated hermes kaufmann fundsNew enterprise associates

Regulus Therapeutics Inc (NASDAQ:RGLS) Q3 2022 Earnings Call Transcript

Operator: Hello, and welcome to the Regulus Therapeutics Inc. Q3 2022 Earnings Conference Call. . I would now like to turn the conference over to Chief Financial Officer, Cris Calsada.

United statesCrispina calsadaYanan zhuJay haganCris calsadaDenis dryginRegulus therapeutics incAmerican society of nephrology kidney weekRegulus therapeuticsCall transcript novemberChief financial officerRegulus therapeutics thirdChief executive officerChief scientificPrivate securities litigation reform actAmerican society

vimarsana © 2020. All Rights Reserved.